Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, PhD, as Vice President of Research and Development

Source: Aerie Pharmaceuticals

Aerie Pharmaceuticals announced the appointment of Tori Arens as Vice President of Drug Product Manufacturing, reporting to Kenneth Ruettimann, PhD, Aerie’s Vice President of Manufacturing. Aerie also announced the appointment of Eric Carlson, PhD, as Vice President of Research and Development, reporting to Casey Kopczynski, PhD, Aerie’s Chief Scientific Officer.

Ms. Arens will be responsible for defining and implementing drug product development and manufacturing strategies for the clinical and commercial supply of Aerie’s products. Ms. Arens previously held related leadership positions at Biogen and Eisai, and holds an M.S. in Pharmaceutics from The University of North Carolina at Chapel Hill.

Dr. Carlson will provide strategic direction and leadership for Aerie’s research and development activities aimed at advancing the Aerie pipeline. Dr. Carlson was most recently Senior Global Program Head of Ophthalmology at Alcon Pharmaceuticals/Novartis. He was also previously Assistant Professor, Department of Ophthalmology and Visual Sciences, Case Western Reserve University, and holds a PhD in Cell and Molecular Biology from the University of Cincinnati College of Medicine.

In connection with the acceptance of their positions, Ms. Arens and Dr. Carlson on a combined basis will receive awards totaling 48,750 stock options and 22,750 shares of restricted stock. The stock options will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date; the restricted stock will vest over a period of 4 years in four equal annual installments on each anniversary of the hire date. These awards were made outside of Aerie’s stockholder-approved equity incentive plan and were approved by the company’s Compensation Committee as an inducement material to Ms. Arens and Dr. Carlson entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.

Related Content